Search

B Presenter: b Ding Ding MD, ScM | Johns Hopkins University School of Medicine B Background: b Circulating tumor cell (CTC) subtypes have been used as new biomarkers to predict early or late recurrence and response to treatment for pancreatic cancer. Both epithelial CTC (eCTC) and epithelial/mesenchymal CTC (mCTC) subtypes were used to predict recurrence from the CTC testing time within 9-15months after surgery. On multi-variable cox model including pathological covariates, neo-adjuvant, and adjuvant chemotherapy status, high eCTCs was a risk factor for recurrence since date of CTC testing(Hazard Ratio = 4.41; 95% CI [1.13, 17.23]; p=0.033). [Extracted from the article]

B Presenter: b A. Floortje van Oosten MD | Johns Hopkins University School of Medicine B Background: b Improved systemic and radiation therapies administered as induction therapy have driven a trend of more aggressive operations in patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) that was historically considered technically unresectable. Herein, we present a technical report describing our surgical experience of tumors considered locally advanced with long segment encasement of the superior mesenteric vein (SMV), celiac axis (CA), or the inferior pancreaticoduodenal artery (IPDA) or gastroduodenal artery (GDA) preluding distal pancreatectomy-celiac axis resection (DP-CAR). The option then remains to keep the mesocaval shunt and implant the other branch into the portal vein or to transpose the mesocaval shunt to the portal vein. [Extracted from the article]

B Presenter: b Alina Hasanain MD | Johns Hopkins University School of Medicine B Background: b Outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) remain poor and are predominantly driven by aggressive systemic disease. The aim of the current study was to assess whether CTC characteristics are associated with the impact of a delay in initiation of adjuvant therapy on patient outcomes. [Extracted from the article]